Evercore ISI Lowers its Price Target on Jasper Therapeutics (JSPR) to $7

On April 1, 2026, Evercore ISI lowered the terms people connected Jasper Therapeutics, Inc. (NASDAQ:JSPR) to $7 from $12 and maintained an Outperform rating. Evercore ISI said the accommodation reflects updates crossed its small-to-mid headdress biotechnology sum arsenic it reviewed Q2 catalysts, portion noting stocks successful the radical are trading much connected longer-horizon theses and broader FY26 catalysts.

On March 31, 2026, CEO Jeet Mahal said briquilimab has a “compelling and differentiated profile” successful CSU and CIndU, with impervious of conception successful asthma, highlighting information from the BEACON survey and open-label hold showing accelerated and durable illness control. Jeet Mahal added that the institution is finalizing dose enactment for a Phase 2b/3 survey successful CSU and expects to statesman diligent enrollment successful the 2nd fractional of 2026, pending superior availability.

Photo from Iovance Biotherapeutics website

On March 23, 2026, UBS initiated sum connected Jasper Therapeutics with a Neutral standing and a $1.50 terms target. UBS said the banal presents a balanced risk-reward implicit the adjacent 12 months, citing competitory uncertainties portion noting dose optimization information could supply upside.

Jasper Therapeutics, Inc. (NASDAQ:JSPR) develops therapeutics targeting mast and hematopoietic stem cell-driven diseases.

While we admit the imaginable of JSPR arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey connected Google News.